НОВЫЕ СИНДРОМЫ И ПАТТЕРНЫ ОСТРОЙ ОККЛЮЗИИ КОРОНАРНЫХ АРТЕРИЙ. ОБЗОР ЛИТЕРАТУРЫ.
2023 жыл | Шығарылым: 6 | Беттер: 171-180
КЛОНАЛЬНЫЙ ГЕМОПОЭЗ С НЕОПРЕДЕЛЕННЫМ ПОТЕНЦИАЛОМ И РИСК РАЗВИТИЯ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА
2023 жыл | Шығарылым: 6 | Беттер: 161-170
КЛИНИЧЕСКИЕ И СОЦИАЛЬНО-ДЕМОГРАФИЧЕСКИЕ ХАРАКТЕРИСТИКИ ПАЦИЕНТОВ С ПСИХИЧЕСКИМИ И ПОВЕДЕНЧЕСКИМИ РАССТРОЙСТВАМИ В ПОСТКОВИДНОМ ПЕРИОДЕ
2023 жыл | Шығарылым: 6 | Беттер: 152-160
ПРОБЛЕМНОЕ ИСПОЛЬЗОВАНИЕ СОЦИАЛЬНЫХ СЕТЕЙ И ПСИХОЛОГИЧЕСКОЕ БЛАГОПОЛУЧИЕ ГОРОДСКИХ И СЕЛЬСКИХ ПОДРОСТКОВ КАЗАХСТАНА
2023 жыл | Шығарылым: 6 | Беттер: 140-151
INFLUENCE OF THE COMPOSITION OF “VOLCANO MINERAL” PLANT AND ANIMAL RAW MATERIALS ON HUMORAL AND CELLULAR STRUCTURE OF THE IMMUNE SYSTEM
2023 жыл | Шығарылым: 6 | Беттер: 133-139
RETROSPECTIVE ANALYSIS OF PATIENTS WITH OBLITERATING ATHEROSCLEROSIS OF THE LOWER EXTREMITY ARTERIES IN THE ABAI REGION OF THE REPUBLIC OF KAZAKHSTAN
2025 жыл | Шығарылым: 3 | Беттер: 42-52
EFFICACY OF PHOTODYNAMIC THERAPY IN THE TREATMENT OF CERVICAL PRECANCEROUS CONDITIONS CAUSED BY HUMAN PAPILLOMAVIRUS
2025 жыл | Шығарылым: 3 | Беттер: 53-63
DOMESTIC VIOLENCE AS A PUBLIC HEALTH CHALLENGE: RESULTS OF A MASS SOCIOLOGICAL STUDY IN TURKISTAN REGION
2025 жыл | Шығарылым: 3 | Беттер: 64-69
ASSESSMENT OF DEPRESSION, FATIGUE, AND PSYCHOLOGICAL WELL-BEING IN PATIENTS AFTER STROKE: RESULTS OF A CROSS-SECTIONAL STUDY USING THE BECK, FAS, AND MHC-SF SCALES
2025 жыл | Шығарылым: 3 | Беттер: 70-78
SOCIAL DETERMINANTS OF HEALTH AMONG UNEMPLOYED YOUTH IN KAZAKHSTAN: HOW ECONOMIC DISPARITY AFFECTS QUALITY OF LIFE
2025 жыл | Шығарылым: 3 | Беттер: 79-87
USING OF ATORIS AT FEMALES WITH ARTERIAL HYPERTENSION AND HYPERLIPIDEMIA
So, medicine Atoris is may be used as high effective lipid lowering drug for secondary prophylaxis of cardiovascular compli-cations at females with high risk of ischemic heart disease.
Толығырақ
2012 жыл | Шығарылым: 2 | Беттер: 40-42
ARTERIAL HYPERTENSION AT OLD AGE PATIENTS
Problem of arterial hypertension at old age patients is connected with it’s wide spreading and tendency to aging of popu-lation. In old age there are different risk factors and accompanying diseases, which permit to say about that group of patients are in high or very high risk of cardiovascular complications not depending on degree of increasing of blood pressure.
Толығырақ
2012 жыл | Шығарылым: 2 | Беттер: 38-40
DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (CHF)
This lecture consist of actuality, definition, main etiological factors of chronic heart failure and diagnostic criteria. And there is medicamentous therapy and principles of surgical and electrophysiological methods of treatment of CHF in this lecture.
Толығырақ
2012 жыл | Шығарылым: 2 | Беттер: 32-37
CALCIUM CHANNELS BLOCKERS - A ROLE IN MODERN THERAPY OF CARDIOVASCULAR DISEASES: IN FOCUS – DILTIAZEM
Calcium channels blockers – group of the drugs which basic property is ability to brake a calcium current inside of smooth muscle cells through the special channels named “slow calcium channels”. Diltiazem Lannacher renders cardioprotective action with antioxidative effect, angioprotective action, antiagregant action, antiatherogenous action, nephroprotective action, cerebroprotective action.
Толығырақ
2012 жыл | Шығарылым: 2 | Беттер: 24-34
DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AT TREATMENT OF ARTERIAL HYPERTENSION: LERKAMEN
Arterial hypertension (AH) is independent risk factor of myocardial infarction, brain stroke, chronic heart failure (CHF) and hypertensive nephropathy, death from cardiovascular diseases.
Main aim of therapy of AH is maximal decreasing of risk of development of cardiovascular morbidity and mortality.
This lecture includes data about pharmacodynamics and therapeutic efficiency of dihydropyridine calcium channel blocker Lerkamen, its advantages, indications and contraindications, metabolic neutrality, organ protection.
Толығырақ
Main aim of therapy of AH is maximal decreasing of risk of development of cardiovascular morbidity and mortality.
This lecture includes data about pharmacodynamics and therapeutic efficiency of dihydropyridine calcium channel blocker Lerkamen, its advantages, indications and contraindications, metabolic neutrality, organ protection.
Толығырақ
2012 жыл | Шығарылым: 2 | Беттер: 18-24